Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sandoz
- Enrollment
- 105
- Locations
- 6
- Primary Endpoint
- Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)
Study Overview
Brief Summary
To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •must be able to speak, read, and understand English
- •exhaled Nitrous Oxide levels must be greater than or equal to 60 ppb at screening and greater than or equal to 55 ppb at Visits 2, 9, and 16
- •must have history of at least 6 months of chronic, but stable asthma
- •except for the presence of asthma, subjects must be in general good health
Exclusion Criteria
- •past or present history of experiencing allergic reaction to medications used in this study
- •subjects must not be receiving ongoing regular treatment with inhaled corticosteroids
- •subjects must not have ragweed allergy
- •subjects must have no recent history of respiratory infections for at least 1 month prior to screening and until the end of the study
Outcomes
Primary Outcomes
Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)
Time Frame: Baseline to Day 7 of each treatment cycle (total duration about 8 - 10 weeks)
Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.
Secondary Outcomes
No secondary outcomes reported